Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://www.ncbi.nlm.nih.gov/pubmed/30356868
http://dx.doi.org/10.3389/fneur.2018.00842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://www.ncbi.nlm.nih.gov/pubmed/30356868
http://dx.doi.org/10.3389/fneur.2018.00842

Ejemplares similares